In the preceding three months, 6 analysts have released ratings for Accolade (NASDAQ:ACCD), presenting a wide array of perspectives from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $7.25, with a high estimate of $8.00 and a low estimate of $5.00. Experiencing a 18.72% decline, the current average is now lower than the previous average price target of $8.92.

Understanding Analyst Ratings: A Comprehensive Breakdown

In examining recent analyst actions, we gain insights into how financial experts perceive Accolade. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Capture valuable insights into Accolade's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Accolade analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Delving into Accolade's Background

Unraveling the Financial Story of Accolade

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Over the 3 months period, Accolade showcased positive performance, achieving a revenue growth rate of 18.49% as of 31 May, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Accolade's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -24.98% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Accolade's ROE stands out, surpassing industry averages. With an impressive ROE of -6.27%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Accolade's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.55%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Accolade's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.55.

The Significance of Analyst Ratings Explained

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.